Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chinese Patent Office
Citi
McKesson
Cantor Fitzgerald
Teva

Generated: July 21, 2019

DrugPatentWatch Database Preview

Patent: 5,968,825

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,968,825
Title: Antisense oligonucleotides complementary to the primary transcript of the human c-fes protooncogene
Abstract:The following description sets forth antisense (AS) oligonucleotides (ODNs) complementary to the primary transcript of the human c-fes protooncogene and their use to inactivate said transcript. All-trans retinoic acid (ATRA) is reported to be used as a differentiation inducer on cells pretreated with said AS-ODNs to induce apoptosis of leukemic blast cells.
Inventor(s): Ferrari; Sergio (Modena, IT), Manfredini; Rossella (Campogalliano, IT)
Assignee: Istituto Biochimico Italiano Giovanni Lorenzini S.P.A. (Milan, IT)
Application Number:08/859,389
Patent Claims:see list of patent claims

Details for Patent 5,968,825

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up Istituto Biochimico Italiano Giovanni Lorenzini S.P.A. (Milan, IT) ➤ Sign Up RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up Istituto Biochimico Italiano Giovanni Lorenzini S.P.A. (Milan, IT) ➤ Sign Up RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up Istituto Biochimico Italiano Giovanni Lorenzini S.P.A. (Milan, IT) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Accenture
Mallinckrodt
Federal Trade Commission
Argus Health
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.